Can you explain, in simple terms, the roles of GLP‑1 and GIP and how GLP‑1 receptor agonists and dual GLP‑1/GIP agonists are used to treat type‑2 diabetes and obesity, including their mechanisms of action and common side effects?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Understanding GLP-1 and GIP: A Simple Guide for Students

What Are GLP-1 and GIP?

Think of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) as natural hormones your gut releases after you eat. They're called "incretins" and act like messengers telling your body what to do with the food you just consumed 1.

GLP-1's main jobs:

  • Tells your pancreas to release insulin (but only when blood sugar is high—smart, right?)
  • Stops your pancreas from releasing glucagon (which raises blood sugar)
  • Slows down how fast your stomach empties food
  • Makes you feel full and less hungry by acting on your brain 1

GIP's main jobs:

  • Also stimulates insulin release when blood sugar rises
  • Works on fat cells to help with metabolism
  • Acts on your brain to control appetite
  • Has a unique feature: it can actually increase glucagon during low blood sugar (preventing dangerous drops) but decreases it during high blood sugar 1, 2

How These Medications Work

GLP-1 Receptor Agonists (like semaglutide and liraglutide)

These are synthetic versions that mimic natural GLP-1 but last much longer in your body 1. They work by activating only the GLP-1 receptor, producing:

For diabetes:

  • Better blood sugar control through increased insulin and decreased glucagon
  • Average weight loss of 5-10% in people with type 2 diabetes
  • In people without diabetes but with obesity, weight loss can reach 14.9% (with semaglutide) 3, 1

Beyond blood sugar:

  • Cardiovascular protection: In the LEADER trial, liraglutide reduced cardiovascular death, heart attack, or stroke by 13% 1
  • Kidney benefits: semaglutide significantly reduced major kidney disease events 3
  • Liver benefits: reduces fat accumulation and inflammation in fatty liver disease 3

Dual GIP/GLP-1 Receptor Agonists (like tirzepatide)

These are the newer, more powerful medications that activate BOTH receptors simultaneously 3, 1. Think of it as hitting two targets at once for amplified effects.

Why they work better for weight loss:

  • Tirzepatide produces 15-20% weight loss—nearly double what single GLP-1 drugs achieve 3
  • At the highest dose (15 mg), weight loss can reach 20.9% 1
  • The American Diabetes Association now recommends dual GIP/GLP-1 agonists as the preferred first choice for people with both type 2 diabetes and obesity 3

The synergy explained:

  • GLP-1 component: suppresses appetite, slows stomach emptying, controls blood sugar
  • GIP component: adds extra appetite control through different brain pathways, improves fat cell health, and provides complementary metabolic effects 2

Common Side Effects (What to Expect)

Gastrointestinal effects are the most common 3:

  • Nausea: affects 25% of patients
  • Vomiting and diarrhea: up to 10% of patients
  • These typically worsen when increasing doses but many people develop tolerance over time 3

Management strategies patients should follow:

  • Eat smaller meals
  • Drink plenty of water
  • Increase dietary fiber
  • Eat slowly and stop when full
  • Avoid high-fat or spicy foods
  • Limit alcohol and carbonated drinks 3

Important safety concerns:

  • Delayed gastric emptying: These medications slow stomach emptying significantly, which can persist even with long-term use 1. This is particularly important for surgical planning.

  • Gallbladder disease: All GLP-1 medications increase risk of gallbladder or biliary disease. Tirzepatide specifically increases this risk 3.

  • Pancreatitis: While data is conflicting, stop the medication immediately if severe abdominal pain occurs with or without nausea/vomiting 3.

  • Thyroid cancer risk: Absolute contraindication if you have personal or family history of medullary thyroid cancer or genetic testing positive for it. These medications stimulate thyroid C cells that express GLP-1 receptors 3.

Clinical Use Summary

For type 2 diabetes with obesity:

  • Dual GIP/GLP-1 agonists (tirzepatide) are now preferred first-line over single GLP-1 agonists due to superior weight loss 3

For obesity without diabetes:

  • Semaglutide (2.4 mg weekly) and liraglutide (3 mg daily) are FDA-approved
  • Tirzepatide produces weight loss previously only seen with bariatric surgery 1, 4

Key principle: These medications must be used long-term. When stopped, patients regain significant weight—studies show 6.9-11.6% weight regain after discontinuation 4. They work best when combined with reduced calorie intake and exercise 3.

References

Related Questions

Given a 30-year-old Black male, 6'5", 320 lb, with hypertension on amlodipine, on a GLP‑1 agonist, G6PD deficiency, labs showing a positive antinuclear antibody with speckled pattern, markedly elevated anti‑U1‑RNP antibody, negative anti‑centromere, anti‑SM, anti‑dsDNA, anti‑SSA/SSB, anti‑Scl‑70, normal complement C3/C4, elevated creatine kinase (≈400‑500 U/L), mildly elevated C‑reactive protein, normal AST/ALT, and an upcoming electromyography, what is the most likely diagnosis (inflammatory myositis associated with mixed connective tissue disease versus necrotizing autoimmune myopathy) and will an abnormal electromyography require a muscle biopsy?
What can a postmenopausal woman with diabetes taking GLP-1 (Glucagon-like peptide-1) receptor agonists do to manage hair loss?
Are GLP-1 (Glucagon-like peptide-1) and GIP (Glucose-dependent insulinotropic polypeptide) medications safe for non-diabetic individuals?
Can tenegliptin and linagliptin be prescribed together?
Does a patient with pre-diabetes and a BMI of 25.5 qualify for a GLP-1 receptor agonist?
Will increasing Vraylar (cariprazine) from 1.5 mg to 2 mg improve the patient's depression and anxiety?
What is the appropriate management for a patient who has been on Vraylar (cariprazine) 1.5 mg daily for three months?
Can anxiety be a sign of manic activation caused by Spravato (esketamine) nasal spray?
What is the appropriate evaluation and management for a patient with fluctuating blood pressure?
What are the recommended initial pressure support ventilation settings (pressure support level, PEEP, FiO₂, trigger sensitivity, and flow‑cycle) for an adult patient?
What is the appropriate pain management regimen for an otherwise healthy 11‑year‑old child undergoing an appendectomy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.